Kidney transplantation--new developments.

F Dahm, M Weber
{"title":"Kidney transplantation--new developments.","authors":"F Dahm,&nbsp;M Weber","doi":"10.1024/1023-9332.9.5.205","DOIUrl":null,"url":null,"abstract":"<p><p>The standard of care for patients with end-stage renal disease is kidney transplantation, which not only confers a survival benefit compared to hemodialysis, but is also cost-effective. The indications, contraindications as well as the preoperative assessment of recipients are discussed. The recurrence rate of the underlying renal disease has to be taken into account, especially in living donation. Growing organ shortage has lead transplant surgeons to accept older, less healthy, and even non-heart-beating donors, with generally good results. Living-donation is safe for the donor, outcome is excellent and plays an increasing role today. It has surpassed the number of cadaveric kidney transplantations in some countries. Many centres now apply laparoscopic donor nephrectomy with low morbidity. Matching for ABO blood group and HLA is routinely performed, as well as pre-transplant crossmatching. The surgical procedure has been standardized and the complication rate is low. Immunosuppressive protocols have evolved over time, and while the optimal regimen has not been defined, the availability of numerous agents allows the regimen to be individualized. New agents are being introduced into clinical practice. With increasing long-term graft survival and thus life-long immunosuppression, cardiovascular disease, de-novo malignancies and infectious complications are major causes of morbidity and mortality of transplant recipients. Effective prophylactic measures are often available, and surveillance protocols are warranted in these patients. Overall, the outcome of renal transplantation is excellent and has improved over time. Future prospects include induction of allograft tolerance, tissue engineering and xenotransplantation.</p>","PeriodicalId":79425,"journal":{"name":"Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera","volume":"9 5","pages":"205-12"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1024/1023-9332.9.5.205","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

The standard of care for patients with end-stage renal disease is kidney transplantation, which not only confers a survival benefit compared to hemodialysis, but is also cost-effective. The indications, contraindications as well as the preoperative assessment of recipients are discussed. The recurrence rate of the underlying renal disease has to be taken into account, especially in living donation. Growing organ shortage has lead transplant surgeons to accept older, less healthy, and even non-heart-beating donors, with generally good results. Living-donation is safe for the donor, outcome is excellent and plays an increasing role today. It has surpassed the number of cadaveric kidney transplantations in some countries. Many centres now apply laparoscopic donor nephrectomy with low morbidity. Matching for ABO blood group and HLA is routinely performed, as well as pre-transplant crossmatching. The surgical procedure has been standardized and the complication rate is low. Immunosuppressive protocols have evolved over time, and while the optimal regimen has not been defined, the availability of numerous agents allows the regimen to be individualized. New agents are being introduced into clinical practice. With increasing long-term graft survival and thus life-long immunosuppression, cardiovascular disease, de-novo malignancies and infectious complications are major causes of morbidity and mortality of transplant recipients. Effective prophylactic measures are often available, and surveillance protocols are warranted in these patients. Overall, the outcome of renal transplantation is excellent and has improved over time. Future prospects include induction of allograft tolerance, tissue engineering and xenotransplantation.

肾移植——新进展。
终末期肾病患者的标准治疗是肾移植,与血液透析相比,肾移植不仅能提高生存期,而且具有成本效益。讨论了适应症、禁忌症以及对受术者的术前评估。必须考虑到潜在肾脏疾病的复发率,特别是在活体捐赠中。器官短缺的加剧导致移植外科医生接受年龄较大、健康状况较差、甚至没有心脏跳动的捐赠者,通常效果良好。活体捐赠对供者来说安全,效果好,在今天发挥着越来越大的作用。在一些国家,它已经超过了尸体肾移植的数量。许多中心现在应用腹腔镜供体肾切除术,发病率低。常规进行ABO血型和HLA的配型,以及移植前交叉配型。手术操作规范,并发症发生率低。免疫抑制方案随着时间的推移而发展,虽然最佳方案尚未确定,但许多药物的可用性允许方案个性化。新的药物正在被引入临床实践。随着移植物长期存活率的增加和终身免疫抑制,心血管疾病、新生恶性肿瘤和感染性并发症是移植受者发病和死亡的主要原因。有效的预防措施通常是可用的,对这些患者的监测方案是必要的。总的来说,肾移植的结果是很好的,并且随着时间的推移而改善。未来的前景包括诱导同种异体移植物耐受、组织工程和异种移植。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信